Shares of Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biotech, more than doubled recently. The market started hurling money at the stock after some mid-stage clinical trial results suggested a bright future for its still-experimental weight management drug.

You don't need to know much about the pharmaceutical industry to recognize a huge opportunity for weight management treatments. That said, investing in biotechs before they have any approved products to sell entails a great deal of risk.

Let's weigh the opportunities in front of Viking Therapeutics against some of its challenges to see if it's a good stock now.

Continue reading

Source Fool.com